Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice

Abstract

Medularni karcinom ščitnice nastane iz nevroendokrinih celic ščitnice, ki izločajo kalcitonin. Kalcitonin je specifičen marker medularnega raka ščitnice. Pri lokalno napredovalem ali metastaskem medularnem raku ščitnice ob simptomtskem progresu prihaja v poštev zdravljenje s tirozin kinaznimi inhibitorji. Registrirani substanci sta vandetanib in cabozantinib, učinkoviti pa sta tudi sorafenib in sunitinib. Izbira zdravljenja je individualizirana glede na breme bolezni in spremljajoče bolezni. Zelo pomembno je tudi podporno (na simptome usmerjeno) zdravljenje.

Keywords

karcinom;rak (medicina);ščitnica;sistemsko zdravljenje;napredovali rak;

Data

Language:	Slovenian
Year of publishing:	2016
Typology:	1.02 - Review Article
Organization:	OI - Institute of Oncology
UDC:	616.441-006-08
COBISS:	2415739
ISSN:	1408-1741
Parent publication:	Onkologija
Views:	2781
Downloads:	668
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Systemic Treatment of Advanced Medullary Thyroid Carcinoma
Secondary abstract:	Medullary thyroid carcinoma originates from neuroendocrine cells of the thyroid which secrete calcitonin. Calcitonin is a specific marker for medullary thyroid cancer. Therapy with tyrosine kinase inhibitors can be applied to treat locally advanced or metastatic medullary thyroid cancer with progressing symptoms. Registered substances used are vandetanib and cabozantinib, and sorafenib and sunitinib are also effective. Treatment is determined individually based on the burden of the cancer and secondary diseases. Supportive treatment (targeted at the symptoms) is also very important.
Secondary keywords:	systemic treatment;medullary thyroid carcinoma;thyroid cancer;
URN:	URN:NBN:SI
Pages:	str. 4-6, 51
Volume:	ǂLetn. ǂ20
Issue:	ǂšt. ǂ1
Chronology:	jun. 2016
ID:	10892941